Voyager Therapeutics (VYGR) Equity Average (2016 - 2025)
Historic Equity Average for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $231.9 million.
- Voyager Therapeutics' Equity Average fell 3033.65% to $231.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.9 million, marking a year-over-year decrease of 3033.65%. This contributed to the annual value of $268.0 million for FY2024, which is 8151.28% up from last year.
- According to the latest figures from Q3 2025, Voyager Therapeutics' Equity Average is $231.9 million, which was down 3033.65% from $258.3 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Equity Average registered a high of $338.2 million during Q2 2024, and its lowest value of $68.0 million during Q2 2022.
- Moreover, its 5-year median value for Equity Average was $187.6 million (2023), whereas its average is $186.5 million.
- Per our database at Business Quant, Voyager Therapeutics' Equity Average tumbled by 4488.9% in 2022 and then surged by 20591.1% in 2023.
- Quarter analysis of 5 years shows Voyager Therapeutics' Equity Average stood at $91.2 million in 2021, then fell by 23.91% to $69.4 million in 2022, then surged by 197.13% to $206.3 million in 2023, then soared by 52.73% to $315.0 million in 2024, then fell by 26.39% to $231.9 million in 2025.
- Its Equity Average was $231.9 million in Q3 2025, compared to $258.3 million in Q2 2025 and $286.2 million in Q1 2025.